Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a…

RT @FrontOncology: New research: Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), hu…

RT @FrontOncology: New research: Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), hu…

New research: Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU… https://t.co/3v6

RT @ciaccio_: How do you manage late onset toxicities (including #livertoxicity) associated with the use of CDK4/6 inhibitors for advanced…